Large antibody study offers hope for coronavirus vaccine efforts

Antibodies that people make to fight the new coronavirus last for at least four months after diagnosis and do not fade quickly, as some earlier reports suggested, scientists have found

Coronavirus, vaccine, covid, drugs, tests, clinical trials
AP Washington
1 min read Last Updated : Sep 02 2020 | 10:36 AM IST

Antibodies that people make to fight the new coronavirus last for at least four months after diagnosis and do not fade quickly, as some earlier reports suggested, scientists have found.

Tuesday's report, from tests on more than 30,000 people in Iceland, is the most extensive work yet on the immune system's response to the virus and is good news for efforts to develop vaccines.

If a vaccine can spur production of long-lasting antibodies like natural infection does, it gives hope that immunity to this unpredictable and highly contagious virus may not be fleeting, independent experts from Harvard University and the US National Institutes of Health wrote in a commentary published with the study in the New England Journal of Medicine.

One of the big mysteries of the pandemic is whether having had the coronavirus helps protect against future infection and for how long. Some smaller studies previously suggested that antibodies disappear quickly and that some people with few or no symptoms may not make many at all.

The new study was done by Reykjavik-based deCODE Genetics, a subsidiary of the US biotech company Amgen, with several hospitals, universities and health officials in Iceland.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Sep 02 2020 | 10:28 AM IST

Next Story